VC accommodates Visiogen
This article was originally published in The Gray Sheet
Executive Summary
Synchrony dual optic accommodating intraocular lens maker raises $24 million in a financing round to support clinical development and other efforts relating to its first product. The lead investor was CMEA Ventures. Other supporters included Foundation Medical Partners and Three Arch Partners, according to a Feb. 28 announcement. Synchrony obtained a CE mark in June 2006 and is in pivotal trials in the United States. The IOL, which incorporates a customized spring-loading component to change the eye's focus from near to far, has been implanted in more than 400 patients worldwide, Visiogen says. Accommodating IOLs like Synchrony, HumanOptics' 1CU and Eyeonics' CrystaLens are designed to more closely mimic the behavior of natural lenses to better capture distance, intermediate and near vision in a single product (1"The Gray Sheet" Oct. 9, 2006, p. 12)...
You may also be interested in...
Intraocular Lens Makers See Unmet Need For Fully “Accommodating” Product
Integrating the merits of various intraocular lens (IOL) implants into a single "accommodating" IOL remains the Holy Grail of eye care companies
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.